Narcolepsy: Action of Two γ-Aminobutyric Acid Type B Agonists, Baclofen and Sodium Oxybate

Pediatric Neurology

Volumn 41, Issue 1, 2009, Pages 9-16

  Huang, Yu Shu ^a,b   Guilleminault, Christian ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; HLA DQB1 ANTIGEN; MODAFINIL; OXYBATE SODIUM;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; CATAPLEXY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DELTA RHYTHM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; FEMALE; FUNCTION TEST; HUMAN; MALE; MULTIPLE SLEEP LATENCY TEST; NARCOLEPSY; NIGHT SLEEP; PEDIATRIC DAYTIME SLEEPINESS SCALE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RATING SCALE; SLEEP TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADOLESCENT; BACLOFEN; BENZHYDRYL COMPOUNDS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; FOLLOW-UP STUDIES; GABA AGONISTS; HUMANS; MALE; NARCOLEPSY; PHOTOPERIOD; POLYSOMNOGRAPHY; RECEPTORS, GABA-B; SEVERITY OF ILLNESS INDEX; SLEEP; SODIUM OXYBATE; TIME FACTORS;

EID: 66349107313     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2009.02.008     Document Type: Article

References (33)

1. Nevsimalova S. Narcolepsy in children and adolescents. In: Bassetti C., Billiard M., and Mignot E. (Eds). Narcolepsy and hypersomnia (2007), Informa Healthcare, New York 67-75
2. Guilleminault C., and Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 43 (1998) 135-142
3. Murali H., and Kotagal S. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 29 (2006) 1025-1029
4. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 3 (1964) 433-451
5. Roth R.H., and Giarman N.J. Natural occurrence of γ-hydroxybutyric acid in mammalian brain. Biochem Pharmacol 19 Suppl. 1 (1970) 1087-1093
6. Walters J., and Roth R.H. γ-Hydroxybutyrate: consideration of endogenous role and therapeutic potential. In: Usdin E., Hamburg D.A., and Barchas J.D. (Eds). Neuroregulators and psychiatric disorders (1977), Oxford University Press, New York 403-415
7. Doherty J.D., Hattox S.E., Snead O.C., and Roth R.H. Identification of endogenous γ-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 207 (1978) 130-139
8. Snead III O.C. γ-Hydroxybutyrate. Life Sci 20 (1977) 1935-1943
9. Kuschinsky W., Suda S., and Sokoloff L. Influence of γ-hydroxybutyrate on the relationship between local cerebral glucose utilization and local cerebral blood flow in the rat brain. J Cereb Blood Flow Metab 5 (1985) 58-64
10. Gessa G.L., Vargiu L., Crabai F., Boero G.C., Caboni F., and Camba R. Selective increase of brain dopamine induced by γ-hydroxybutyrate. Life Sci 5 (1966) 1921-1930
11. Roth R.H. Striatal dopamine and γ-hydroxybutyrate. Pharmacol Ther [B] 2 (1976) 71-88
12. Broughton R., and Mamelak M. γ-Hydroxybutyrate in the treatment of narcolepsy: a preliminary report. In: Guilleminault C., Dement W.C., and Passouant P. (Eds). Narcolepsy: proceedings of the First International Symposium on Narcolepsy, July 1975, Montpellier, France (1976), Spectrum Publications, New York 659-668
13. U.S. Xyrem Multicenter Study Group. A randomized double blind placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo on the treatment of narcolepsy. Sleep 25 (2002) 42-49
14. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 5 (2004) 119-123
15. Black J., and Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29 (2006) 939-946
16. Mamelak M., Black J., Montplaisir J., and Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27 (2004) 1327-1334
17. Pen R.D., and Kroin J.S. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1 8385 (1984) 1078
18. Albright A.L., Cervi A., and Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265 (1991) 1418-1422
19. Bensmail D., Quera Salva M.A., Roche N., et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 67 (2006) 1432-1436
20. Guilleminault C., and Flagg W. Effect of baclofen on sleep-related periodic leg movements. Ann Neurol 15 (1984) 234-239
21. Darbari F.P., Melvin J.J., Piatt Jr. J.H., Adirim T.A., and Kothare S.V. Intrathecal baclofen overdose followed by withdrawal: clinical and EEG features. Pediatr Neurol 33 (2005) 373-377
22. U.S. Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 43 (1998) 88-97
23. American Academy of Sleep Medicine. International classification of sleep disorders: diagnostic and coding manual. 2nd ed. (2005), American Academy of Sleep Medicine, Westchester, IL
24. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14 (1991) 540-545
25. Drake C., Nickel C., Burduvali E., Roth T., Jefferson C., and Pietro B. The Pediatric Daytime Sleepiness Scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep 26 (2003) 455-458
26. American Academy of Sleep Medicine. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 22 (1999) 667-689
27. American Sleep Disorders Association. Recording and scoring leg movements: The Atlas Task Force. Sleep 16 (1993) 748-759
28. Roehrs T., Carskadon M.A., Dement W.C., et al. Daytime sleepiness and alertness. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and practice of sleep medicine. 4th ed (2005), Elsevier-Saunders, Philadelphia 39-50
29. Rechtschaffen A., and Kales A. Manual of standardized terminology, techniques and scoring system for sleep stages of human subjects (1968), U.S. National Institute of Neurological Diseases and Blindness, Bethesda, MD
30. American Sleep Disorders Association. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15 (1992) 173-184
31. Lecendreux M., Maret S., Bassetti C., Mouren M.C., and Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 12 (2003) 347-348
32. Dauvilliers Y., Carlander B., Rivier F., Touchon J., and Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56 (2004) 905-908
33. Zuberi S.M., Mignot E., Ling L., and McArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. [Abstract]. J Sleep Res 13 Suppl. 1 (2004) 828